Overview

A Phase II Study of MEDI-507, Administered by Injection to Adults With Psoriasis

Status:
Completed
Trial end date:
2003-07-01
Target enrollment:
Participant gender:
Summary
To compare disease activity, as measured by PASI score, of three MEDI-507 dosing (injection)regimens vs. placebo.
Phase:
Phase 2
Details
Lead Sponsor:
MedImmune LLC
Treatments:
Antibodies
Antibodies, Monoclonal